Journal:
Article Title: Evidence Against a Direct Antiviral Activity of the Proteasome during the Early Steps of HIV-1 Replication
doi: 10.1016/j.virol.2007.01.018
Figure Lengend Snippet: Left panel: P4.R5 cells were pretreated with MG-132 (25 μM) or nothing for 5 hours. The cells were then washed and exposed to 150 μM Suc-LLVY-AMC (with or without 25 μM MG-132) immediately or after a 2- or 5-hour incubation. Right panel: P4.R5 cells were pretreated with bortezomib (1 μM) or nothing for 5 hours. The cells were then washed and exposed to 150 μM Suc-LLVY-AMC (with or without 1 μM bortezomib) immediately or after a 2- or 5-hour incubation. Measurements were taken every 3 minutes in a fluorometer; the cells were maintained at 37° C. Each point represents the average of 3 measurements (C.V. < 1% in all cases). “LLVY” is suc-LLVY-AMC.
Article Snippet: Fluorogenic Proteasome Substrate III Suc-Leu-Leu-Val-Tyr-AMC (Suc-LLVY-AMC) was purchased from Axxora (#BST-S-280) and resuspended in DMSO.
Techniques: Incubation